- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Mast cell stabilizers.
Displaying page 1 of 1.
EudraCT Number: 2005-004768-22 | Sponsor Protocol Number: C-05-30 | Start Date*: 2006-06-12 | |||||||||||
Sponsor Name:ALCON ITALIA | |||||||||||||
Full Title: Clinical study of the mast-cell stabilizing effects of the Olopatadine using the Conjunctival Allergen Challeenge model | |||||||||||||
Medical condition: subjects with a clinical history of seasonal allergic conjunctivitis, but asymptomatic and free of any topical or systemic medication at baseline | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012446-23 | Sponsor Protocol Number: 192371-016 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Allergan Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 months ... | |||||||||||||
Medical condition: Atopic Keratoconjunctivitis is a bilateral, inflammatory external ocular disease. A serious disease driven by chronic inflammation of the cornea, conjunctiva and lower lid. AKC is commonly presen... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) CZ (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005293-22 | Sponsor Protocol Number: D589GC00003 | Start Date*: 2014-08-06 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004336-16 | Sponsor Protocol Number: CC-93538-EE-001 | Start Date*: 2021-09-29 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject... | |||||||||||||
Medical condition: EOSINOPHILIC ESOPHAGITIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) PT (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018316-32 | Sponsor Protocol Number: D589GC00002 | Start Date*: 2010-11-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, randomized, blinded, 5-period cross-over, placebo and activecontrolled, multicenter, dose-finding study of single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pM... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018315-15 | Sponsor Protocol Number: D589GC00001 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) LV (Completed) HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005212-22 | Sponsor Protocol Number: CC-93538-AD-001 | Start Date*: 2021-09-10 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Se... | |||||||||||||
Medical condition: ATOPIC DERMATITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
